EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effectiveness and Safety of Montelukast as an Adjuvant Therapy to Isotretinoin Treatment of Acne Vulgaris: A Randomized Controlled Trial

Rima Alhalabi, Ahmad Alhalabi, Dima Alhalabi, Manal Mouhamad

SKIN The Journal of Cutaneous Medicine · 11.05.2026 · 10 (3) · 3098-3107

DOI: 10.25251/jfwx0x58 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 11.05.2026. Verfasst von Rima Alhalabi und 3 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Isotretinoin effectively targets all acne-related pathological mechanisms but is associated with various side effects. On the other hand, montelukast serves as an antagonist to LB4, which is an important mediator in acne pathogenesis.

Objectives

This study aimed to compare the efficacy of montelukast as an adjuvant treatment to isotretinoin versus isotretinoin alone for moderate acne vulgaris and to evaluate treatment tolerability by monitoring side effects. Materials and Methods A randomized comparative prospective trial included 40 patients from the Dermatology and Venereology Hospital at Damascus University. They were assigned into two groups: group A received montelukast (10mg/day) with isotretinoin (20 mg/day for 10 days, followed by 0.6 mg/kg/day for three months), while group B received isotretinoin alone (20 mg/day for 10 days, followed by 0.6 mg/kg/day for three months). Follow-ups occurred on the 40th day and then monthly, assessing GAGS, comedones, inflammatory lesions, total lesions, and side effects at each visit. Additionally, patient satisfaction was assessed during the final visit.

Results

Adding montelukast to isotretinoin significantly reduced GAGS, comedones, inflammatory lesions, and total lesions, with statistically significant differences between the beginning and end of treatment. By evaluating patients at the end of treatment period, there were significant statistical differences between the two treatment groups regarding GAGS, inflammatory lesions, total lesions, and patient satisfaction, with more side effects reported in the isotretinoin group.

Conclusion

Montelukast combined with isotretinoin is an effective treatment for moderate acne vulgaris, outperforming isotretinoin alone with fewer side effects.

Zitieren

APA

Alhalabi, R., Alhalabi, A., Alhalabi, D., & Mouhamad, M. (2026). Effectiveness and Safety of Montelukast as an Adjuvant Therapy to Isotretinoin Treatment of Acne Vulgaris: A Randomized Controlled Trial. SKIN The Journal of Cutaneous Medicine, 10(3), 3098-3107. https://doi.org/10.25251/jfwx0x58

Vancouver

Alhalabi R, Alhalabi A, Alhalabi D, Mouhamad M. Effectiveness and Safety of Montelukast as an Adjuvant Therapy to Isotretinoin Treatment of Acne Vulgaris: A Randomized Controlled Trial. SKIN The Journal of Cutaneous Medicine. 2026;10(3):3098-3107. doi:10.25251/jfwx0x58

BibTeX
@article{Alhalabi2026,
  author = {Alhalabi, Rima and Alhalabi, Ahmad and Alhalabi, Dima and Mouhamad, Manal},
  title = {Effectiveness and Safety of Montelukast as an Adjuvant Therapy to Isotretinoin Treatment of Acne Vulgaris: A Randomized Controlled Trial},
  journal = {SKIN The Journal of Cutaneous Medicine},
  year = {2026},
  volume = {10},
  number = {3},
  pages = {3098--3107},
  doi = {10.25251/jfwx0x58}
}
Kostenlos starten →